Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 44-51

  Du, Bo Yu ^a   Song, Wei ^a   Bai, Lu ^b   Shen, Yan ^a   Miao, Shi Ying ^a   Wang, Lin Fang ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Apoptosis; Bortezomib; Doxorubicin; Neuroblastoma; Synergistic effects

Indexed keywords

BORTEZOMIB; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; HUMANS; NEUROBLASTOMA; PYRAZINES;

EID: 84862799762     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000335603     Document Type: Article

References (37)

1. Schor NF: New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther 2009; 122: 44-55.
2. Park JR, Eggert A, Caron H: Neuroblastoma: Biology, prognosis, and treatment (review). Pediatr Clin North Am 2008; 55: 97-120, x.
3. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr., Castle VP: Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008; 7: 135-145.
4. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P: Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-1601.
5. Nawrocki ST, Carew JS, Dunner K Jr., Boise LH, Chiao PJ, Huang P, Abbruzzese JL, Mc-Conkey DJ: Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510-11519.
6. An WG, Hwang SG, Trepel JB, Blagosklonny MV: Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276-1283.
7. Fribley A, Zeng Q, Wang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24: 9695-9704.
8. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr., Lowe SW, Soengas MS: Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications. Cancer Res 2005; 65: 6294-6304.
9. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A: Effect of bortezomib on human neuroblastoma: Analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 2008; 7: 50.
10. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003; 101: 2377-2380.
11. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campag -naro E, Brozo C, Braun T, Talpaz M, Ka -minski MS: Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009; 27: 5015-5022.
12. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
13. van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G: The proteasome inhibitor bortezomib inhibits the release of NF?B-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009; 27: 92-98.
14. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B: Activation of nuclear factor-?B during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochem J 2002; 367: 729-740.
15. Wu J, Harris NL, Inge TH: Nuclear factor-?B and apoptosis inducing factor activation by doxorubicin analog WP744 IN SH-SY5Y neuroblastoma cells. J Surg Res 2004; 122: 231-239.
16. Gangadharan C, Thoh M, Manna SK: Inhibition of constitutive activity of nuclear transcription factor ?B sensitizes doxorubicinresistant cells to apoptosis. J Cell Biochem 2009; 107: 203-213.
17. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S: Rapamycin inhibits doxorubicin-induced NF-?B/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004; 40: 2829-2836.
18. Du B, Jiang L, Xia Q, Zhong L: Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006; 52: 23-28.
19. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
20. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
21. Cohen N, Betts DR, Rechavi G, Amariglio N, Trakhtenbrot L: Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-NSH neuroblastoma cell line. Cancer Genet Cytogenet 2003; 143: 80-84.
22. Biedler JL, Helson L, Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33: 2643-2652.
23. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-5405.
24. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC: Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006; 7: 441-448.
25. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J Jr.: Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006; 28: 439-446.
26. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006; 98: 1142-1157.
27. Wagner LM, Danks MK: New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009; 107: 46-57.
28. Morgensztern D, Baggstrom MQ, Pillot G, Tan B, Fracasso P, Suresh R, Wildi J, Govindan R: A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors. Chemotherapy 2009; 55: 441-445.
29. Muller I, Niethammer D, Bruchelt G: Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (review). Int J Mol Med 1998; 1: 491-494.
30. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H: Doxorubicin (Adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990; 47: 219-231.
31. Ferguson LR, Denny WA: Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res 2007; 623: 14-23.
32. Liu SY, Song SX, Lin L, Liu X: Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 2010; 56: 101-107.
33. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ: A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 2008; 63: 99-107.
34. Manochakian R, Miller KC, Chanan-Khan AA: Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma (review). Clin Lymphoma Myeloma 2007; 7: 266-271.
35. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW Jr.: NF-?B activation mediates doxorubicin-induced cell death in Ntype neuroblastoma cells. J Biol Chem 2001; 276: 48921-48929.
36. Bian X, Opipari AW Jr., Ratanaproeksa AB, Boitano AE, Lucas PC, Castle VP: Constitutively active NF?B is required for the survival of S-type neuroblastoma. J Biol Chem 2002; 277: 42144-42150.
37. Lee TK, Lau TC, Ng IO: Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002; 49: 78-86.